

Recommended cash offer (the "Offer") by AstraZeneca UK Limited ("AstraZeneca") for Cambridge Antibody Technology Group plc ("CAT").

NOTE: THE INFORMATION RELATING TO THE OFFER IS BEING MADE AVAILABLE ON THIS WEBSITE BY ASTRAZENECA IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE OFFER CANNOT BE VALIDLY ACCEPTED BY HOLDERS OF CAT SHARES OR ANY OTHER PERSONS THROUGH MEANS OF DOWNLOADING A COPY OF ANY DOCUMENTS RELATING TO THE OFFER FROM THIS WEBSITE

Access to the Offer

Please read this notice carefully - it applies to all persons who view this part of the website and, depending upon who you are and where you live, it may affect your rights. This part of the site contains information on the Offer. Please note that as the Offer progresses, the disclaimer set out below may be altered or updated. You should read it in full each time you visit this part of the website.

For regulatory reasons, we have to ensure you are aware of the appropriate regulations for the country which you are in. To allow you to view details relating to the Offer, you have to read the following then press "I agree". If you are unable to agree you should press "I disagree" and you will not be able to view any such details.

Offer into the United States

In the United States, AstraZeneca has filed a Tender Offer Statement containing the Offer Document and other related documentation with the US Securities and Exchange Commission (the "SEC") on Schedule TO and CAT has filed a Solicitation/Recommendation Statement with the SEC on Schedule 14D-9. Free copies of the Schedule TO, the Schedule 14D-9 and the other related documents filed by AstraZeneca or CAT in connection with this Offer available are on the SEC's website at <http://www.sec.gov>. The Offer Document and Forms of Acceptance accompanying the Offer Document will be made available to all CAT Shareholders at no charge to them.

CAT Shareholders are advised to read the Offer Document and the accompanying Forms of Acceptance because they contain important information. CAT Shareholders in the United States are also advised to read the Tender Offer Statement and the Solicitation/Recommendation Statement because they contain important information.

Overseas persons

Viewing this information may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person are allowed to view this information.

In particular, the Offer will not be made, directly or indirectly, in or into, any jurisdiction where to do so would constitute a breach of securities laws in that jurisdiction, and the Offer is not capable of acceptance from or within any such jurisdiction. Accordingly, the information on this website must not be viewed if you are in or a resident of any such jurisdiction where to do so would constitute a breach of securities laws in that jurisdiction. No copies of any documents related to the Offer are being, or may be, mailed or otherwise forwarded, distributed or sent in or into any jurisdiction where to do so would constitute a breach of securities laws in that jurisdiction, and persons accessing or receiving such documents (including, without limitation, custodians, nominees and trustees) must not mail, distribute or send them in, into or from such jurisdictions or use such mails or any such means, instrumentality or facility for any purpose directly or indirectly in connection with the Offer, and so doing may invalidate any purported acceptance of the Offer.

If you are not permitted to view the information on this website, or viewing the information would result in a breach of the above, or you are in any doubt as to whether you are permitted to view the information, please exit this web page by clicking on the "I disagree" box below.

The availability of the Offer to CAT shareholders who are not resident in and citizens of the United Kingdom or the United States may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Such persons should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions. Further details in relation to overseas shareholders are contained in the Offer Document.

Forward-looking statements

The materials found on this website may contain certain forward-looking statements about

AstraZeneca and CAT. Although it is believed that any expectations are based on reasonable assumptions, any forward-looking statements may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. Forward-looking statements have been identified by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. These forward-looking statements are subject to numerous risks and uncertainties. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond AstraZeneca's or CAT's control, include, among other things: difficulties in integrating CAT, unexpected and greater costs arising out of the offer for CAT or the integration of AstraZeneca and CAT; regulatory conditions being imposed on the acquisition of CAT; the loss or expiration of patents, marketing exclusivity or trade marks by either AstraZeneca or CAT; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of delay to new product launches; the difficulties of obtaining and maintaining governmental approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as expected; and the risk of environmental liabilities. For further discussion of factors that may cause AstraZeneca's or CAT's actual results to differ from expectations, you should read their respective most recent UK Annual Reports and filings and submissions with the SEC, including their Annual Reports on Form 20-F and information filed under Form 6-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the document in which they were made. Except as required by law or the UK Listing Rules, neither AstraZeneca nor CAT undertakes any obligation to publicly release any update or revisions to these forward-looking statements to reflect events or circumstances after their time of publication.

Basis of access to the Offer

Access to the electronic version of any documents relating to the Offer are being made available on its website by AstraZeneca in good faith and for information purposes only. Any person seeking access to AstraZeneca's website represents and warrants to AstraZeneca that they are doing so for information purposes only. Making the Offer available in electronic format does not constitute an offer to sell or the solicitation of an offer to buy shares in CAT. Further, it does not constitute a recommendation by AstraZeneca or any other party to sell or buy shares in CAT.

CAT shareholders should seek advice from an independent financial adviser as to the suitability of any action for the individual concerned. Any shareholder action required in connection with the Offer will only be set out in documents sent to or made available to CAT's shareholders by AstraZeneca and any decision made by such shareholders should be made solely and only on the basis of information provided in those documents.

Goldman Sachs International, which is authorised and regulated by the Financial Services Authority is acting exclusively for AstraZeneca and no one else in connection with the Offer and will not be responsible to anyone other than AstraZeneca for providing the protections afforded to clients of Goldman Sachs International nor for providing advice in relation to the Offer or any other matter referred to herein.

Deutsche Bank, which is authorised by Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and by the Financial Services Authority for the conduct of UK business, is acting for AstraZeneca and no one else in connection with the Offer and will not be responsible to any other person for providing the protections afforded to customers of Deutsche Bank, or for providing advice in relation to the Offer or any other matters referred to herein.

Morgan Stanley is acting as financial advisor to CAT and no one else in connection with the Offer and will not be responsible to anyone other than CAT for providing the protections afforded to clients of Morgan Stanley or for providing advice in relation to the Offer or any other matters referred to herein.

JPMorgan Cazenove Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for CAT in connection with the Offer and no one else and will not be responsible to anyone other than CAT for providing the protections afforded to clients of JPMorgan Cazenove Limited, or for providing advice in relation to the Offer or any other matters referred to herein.

Responsibility

The Directors of AstraZeneca accept responsibility for the information contained on this webpage,

other than that relating to the CAT Group. To the best of the knowledge and belief of the Directors of AstraZeneca (who have taken all reasonable care to ensure that such is the case), such information is in accordance with the facts and does not omit anything likely to affect the import of such information.

The Directors of CAT accept responsibility for the information contained on this webpage relating to the CAT Group. To the best of the knowledge and belief of the Directors of CAT (who have taken all reasonable care to ensure that such is the case), such information is in accordance with the facts and does not omit anything likely to affect the import of such information.

Subject to any continuing obligations under applicable law or any relevant listing rules, AstraZeneca expressly disclaims any obligation to disseminate, after the date of the posting of the Offer on this webpage, any updates or revisions to any statements in the Offer to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.